Multiapproach treatment of NK/T-cell lymphoma: l-asparaginase–based regimens (preferentially using pegylated forms or Erwinia asparaginase in patients with antibodies against Escherichia coli asparaginase and/or a low asparaginase activity), with Pgp-insensitive drugs, checkpoint inhibitors allowing cytotoxic T-cell–recognizing EBV antigens (EBNA1, LMP1, or LMP2), derived peptides to kill NK/T lymphoma cells (these T cells may be in vitro expanded against EBV antigens), and anti-CD38 antibodies able to kill NK/T lymphoma cells and to synergize with cytotoxic T cells (CTLs) by their action on regulatory T cells (Tregs). MHC, major histocompatibility complex; TCR, T-cell receptor.